---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-048736"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:54:26.521368+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin closes $850M 5.500% senior notes offering to fund Amicus acquisition

## Summary
- Closed private placement of $850M 5.500% senior notes due 2034 at 100% issue price.
- Net proceeds, combined with $2B term loan B, $800M term loan A, and cash, to fund Amicus acquisition.
- Notes held in escrow; if acquisition not completed by Dec 19, 2026, notes redeemed at par plus accrued interest.
- Notes guaranteed by certain subsidiaries; after closing, Amicus and its subsidiaries will also guarantee.
- Expects to enter $600M senior secured revolving credit facility in connection with the acquisition.

## SEC filing metadata
- accession: 0001193125-26-048736
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/d63881d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-048736
- JSON: https://secwatch.observer/filing/0001193125-26-048736.json
- Plain text: https://secwatch.observer/filing/0001193125-26-048736.txt

## Source-grounded claims
- claim_id: e526acfdacb0ec7c2b07659766d8649165c432c4
  claim: BIOMARIN PHARMACEUTICAL INC incurred senior notes of $850 million aggregate principal amount at 5.500% maturing 2026.
  evidence_excerpt: On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm
- claim_id: d506b5482c34cd5cf1875e2b22420902cb689f05
  claim: BIOMARIN PHARMACEUTICAL INC entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $850 million aggregate principal amount (effective 2026-02-12).
  evidence_excerpt: On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.